FDA Brief

Warning letters Food

FDA warning letter to

Sage Moon Apothecary LLC

MediumIssued Jan 14, 2021Posted Jan 26, 2021Division of Human and Animal Food Operations East I

FDA warned Sage Moon Apothecary that Golden Milk and Elderberry products were unapproved new drugs with disease claims.

What happened

FDA reviewed Sage Moon Apothecary's websites and Facebook page in September, October, and November 2020 and found product pages and posts claiming the products relieve pain, treat arthritis, fibromyalgia, IBS, and migraines, and inhibit flu virus. FDA said these claims make the products drugs intended to treat disease. FDA also said the products are unapproved new drugs and misbranded because they lack adequate directions for use.

What FDA found

  1. FDA treated website and social media claims that the products relieve pain, treat arthritis, fibromyalgia, IBS, migraines, and inhibit flu virus as evidence the products are intended to treat disease.

    section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. FDA said the products are new drugs because they are not generally recognized as safe and effective for those uses and have not received FDA approval.

    sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. FDA said the products are misbranded because they lack adequate directions for use for diseases that a layperson cannot safely diagnose or treat without a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. FDA said introducing or delivering the misbranded products for interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

Within 15 working days of receipt, FDA asks the company to notify it in writing of specific steps taken to correct the violations, prevent recurrence, and provide related documentation. If the company cannot complete corrections in that time, it must state the reason for delay and when it will finish.

Who should pay attention

  • makers of herbal, food, or beverage products that make disease claims
  • online retailers and marketplaces hosting similar product listings
  • brands that use customer testimonials in product marketing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk